Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome : A systematic review and meta-analysis
Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved..
We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane, Embase, and Clinicaltrials.gov. After screening 626 articles, eight studies were included. Data were extracted following the PRISMA guidelines and analyzed using the meta-package by Schwarzer et al. We analyzed 540 patients. The pooled median 3 (1-5) year overall survival was 21% (95% CI 0.08-0.37, I2=91%, n=540). The pooled relapse rate was 58.9% (95% CI 0.38-0.77, I2=93%, n=487) at a median of 1.75 (1-3) years. The pooled 4-year progression- free survival was 34.8% (95% CI 0.15-0.57, I2=72%, n=105). Outcomes of Allo-HSCT for TP53-mutated MDS patients remain poor, with 21% OS at three years; however, Allo-HSCT confers a survival advantage as compared to non-transplant palliative therapies. Our findings suggest the need to explore novel therapeutic agents in prospective clinical trials.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:196 |
|---|---|
| Enthalten in: |
Critical reviews in oncology/hematology - 196(2024) vom: 28. Apr., Seite 104310 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Shahzad, Moazzam [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.critrevonc.2024.104310 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM369132696 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM369132696 | ||
| 003 | DE-627 | ||
| 005 | 20240408232505.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240301s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.critrevonc.2024.104310 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM369132696 | ||
| 035 | |a (NLM)38423375 | ||
| 035 | |a (PII)S1040-8428(24)00053-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Shahzad, Moazzam |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Outcomes with allogeneic hematopoietic stem cell transplantation in TP53-mutated myelodysplastic syndrome |b A systematic review and meta-analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved. | ||
| 520 | |a We conducted a systematic review and meta-analysis to evaluate outcomes after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) in TP53-mutated myelodysplastic syndromes (MDS). A literature search was performed on PubMed, Cochrane, Embase, and Clinicaltrials.gov. After screening 626 articles, eight studies were included. Data were extracted following the PRISMA guidelines and analyzed using the meta-package by Schwarzer et al. We analyzed 540 patients. The pooled median 3 (1-5) year overall survival was 21% (95% CI 0.08-0.37, I2=91%, n=540). The pooled relapse rate was 58.9% (95% CI 0.38-0.77, I2=93%, n=487) at a median of 1.75 (1-3) years. The pooled 4-year progression- free survival was 34.8% (95% CI 0.15-0.57, I2=72%, n=105). Outcomes of Allo-HSCT for TP53-mutated MDS patients remain poor, with 21% OS at three years; however, Allo-HSCT confers a survival advantage as compared to non-transplant palliative therapies. Our findings suggest the need to explore novel therapeutic agents in prospective clinical trials | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Systematic Review | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Allogeneic hematopoietic stem cell transplantation | |
| 650 | 4 | |a Myelodysplastic syndrome | |
| 650 | 4 | |a Outcomes | |
| 650 | 4 | |a TP53 mutation | |
| 650 | 7 | |a TP53 protein, human |2 NLM | |
| 650 | 7 | |a Tumor Suppressor Protein p53 |2 NLM | |
| 700 | 1 | |a Iqbal, Qamar |e verfasserin |4 aut | |
| 700 | 1 | |a Tariq, Ezza |e verfasserin |4 aut | |
| 700 | 1 | |a Ammad-Ud-Din, Mohammad |e verfasserin |4 aut | |
| 700 | 1 | |a Butt, Atif |e verfasserin |4 aut | |
| 700 | 1 | |a Mushtaq, Ali Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Ali, Fatima |e verfasserin |4 aut | |
| 700 | 1 | |a Chaudhary, Sibgha Gull |e verfasserin |4 aut | |
| 700 | 1 | |a Anwar, Iqra |e verfasserin |4 aut | |
| 700 | 1 | |a Gonzalez-Lugo, Jesus D |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelhakim, Haitham |e verfasserin |4 aut | |
| 700 | 1 | |a Ahmed, Nausheen |e verfasserin |4 aut | |
| 700 | 1 | |a Hematti, Peiman |e verfasserin |4 aut | |
| 700 | 1 | |a Singh, Anurag K |e verfasserin |4 aut | |
| 700 | 1 | |a McGuirk, Joseph P |e verfasserin |4 aut | |
| 700 | 1 | |a Mushtaq, Muhammad Umair |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical reviews in oncology/hematology |d 1996 |g 196(2024) vom: 28. Apr., Seite 104310 |w (DE-627)NLM012606006 |x 1879-0461 |7 nnns |
| 773 | 1 | 8 | |g volume:196 |g year:2024 |g day:28 |g month:04 |g pages:104310 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.critrevonc.2024.104310 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 196 |j 2024 |b 28 |c 04 |h 104310 | ||